Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: A prospective, randomized study
Hong Sang Oh
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorCorresponding Author
Dong Ho Lee
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Dr Dong Ho Lee, Department of Internal Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-707, Korea. Email: [email protected]Search for more papers by this authorJi Yeon Seo
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorYu Ri Cho
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorNayoung Kim
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorSook Hyang Jeoung
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorJin Wook Kim
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorJin Hyeok Hwang
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorYoung Soo Park
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorSang Hyub Lee
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorCheol Min Shin
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorHyun Jin Cho
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorHyun Chae Jung
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorIn Sung Song
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorHong Sang Oh
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorCorresponding Author
Dong Ho Lee
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Dr Dong Ho Lee, Department of Internal Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-707, Korea. Email: [email protected]Search for more papers by this authorJi Yeon Seo
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorYu Ri Cho
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorNayoung Kim
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorSook Hyang Jeoung
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorJin Wook Kim
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorJin Hyeok Hwang
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorYoung Soo Park
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorSang Hyub Lee
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorCheol Min Shin
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorHyun Jin Cho
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
Search for more papers by this authorHyun Chae Jung
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorIn Sung Song
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Search for more papers by this authorAbstract
Background and Aims: The eradication rate of proton pump inhibitor (PPI)-based triple therapy for Helicobacter pylori (H. pylori) infection has decreased, mainly due to increasing antibiotic resistance, especially against clarithromycin. It has been reported that a 10-day sequential strategy can produce good outcomes. The aim of this prospective study was to assess the efficacy of sequential therapy as the first-line treatment for the eradication of H. pylori in Korea.
Methods: A total of 116 patients with proven H. pylori infection received 10-day sequential therapy (20 mg rabeprazole and 1 g amoxicillin, twice daily for the first 5 days, followed by 20 mg rabeprazole, 500 mg clarithromycin, and 500 mg metronidazole, twice daily for the remaining 5 days); 130 patients received 7-day triple therapy (20 mg rabeprazole, 500 mg clarithromycin, and 1 g amoxicillin, twice daily for 7 days). Eradication was evaluated by the 13C-urea breath test, 4 weeks after the completion of treatment. Compliance and adverse events were assessed.
Results: The eradication rates of 10-day sequential therapy and PPI-based triple therapy were 79.3% (92/116) and 63% (82/130) by intention-to-treat analysis, respectively (P = 0.005), and 81.9% (91/111) and 64.5% (82/127) by per protocol analysis, respectively (P = 0.003). Mild adverse events occurred in both therapy groups (27.5% vs 23.8%), but both treatments were well tolerated.
Conclusion: The eradication rate of the 10-day sequential therapy regimen was significantly higher than that of PPI-based triple therapy in the Korean population. Ten-day sequential therapy might be effective as a first-line treatment for H. pylori infection in Korea.
References
- 1 McColl KE. Clinical practice. Helicobacter pylori infection. N. Engl. J. Med. 2010; 362: 1597–604.
- 2 Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772–81.
- 3 Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol. 2007; 102: 1808–25.
- 4 Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs standard triple therapies for Helicobacter pylori infection: a meta-analysis. J. Clin. Pharm. Ther. 2009; 34: 41–53.
- 5 Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can. J. Gastroenterol. 2003; 17 (Suppl. B): 36B–40B.
- 6 Zullo A, Rinaldi V, Winn S et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 2000; 14: 715–18.
- 7 Lee JM, Breslin NP, Fallon C, O'Morain CA. Rapid urease tests lack sensitivity in Helicobacter pylori diagnosis when peptic ulcer disease presents with bleeding. Am. J. Gastroenterol. 2000; 95: 1166–70.
- 8 Demir M, Gokturk HS, Ozturk NA, Arslan H, Serin E, Yilmaz U. Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients. South. Med. J. 2009; 102: 1116–20.
- 9 Vaira D, Zullo A, Vakil N et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann. Intern. Med. 2007; 146: 556–63.
- 10 Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J. Clin. Gastroenterol. 2010; 44: 313–25.
- 11 Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am. J. Gastroenterol. 2009; 104: 3069–79. quiz 1080.
- 12 Buzas GM. First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective. World J. Gastroenterol. 2010; 16: 3865–70.
- 13 Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann. Intern. Med. 2008; 148: 923–31.
- 14 Sanchez-Delgado J, Calvet X, Bujanda L, Gisbert JP, Tito L, Castro M. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am. J. Gastroenterol. 2008; 103: 2220–3.
- 15 Choi WH, Park DI, Oh SJ et al. Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea. Korean J. Gastroenterol. 2008; 51: 280–4.
- 16 Kwon JH, Lee DH, Song BJ et al. Ten-day sequential therapy as first-line treatment for Helicobacter pylori infection in Korea: a retrospective study. Helicobacter 2010; 15: 148–53.
- 17 Lee JH, Shin JH, Roe IH et al. Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. Antimicrob. Agents Chemother. 2005; 49: 1600–3.
- 18 Fareed R, Abbas Z, Shah MA. Effect of Helicobacter pylori density on inflammatory activity in stomach. J. Pak. Med. Assoc. 2000; 50: 148–51.
- 19 Egan BJ, Marzio L, O'Connor H, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2008; 13 (Suppl. 1): 35–40.
- 20 Gene E, Calvet X, Azagra R, Gisbert JP. Triple vs quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment. Pharmacol. Ther. 2003; 17: 1137–43.
- 21 Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann. Intern. Med. 2007; 147: 553–62.
- 22 Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int. J. Antimicrob. Agents 2002; 19: 67–70.
- 23 Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007; 56: 1353–7.
- 24 Lee JH, Hong SP, Kwon CI et al. The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication. Korean J. Gastroenterol. 2006; 48: 19–24.
- 25 Kim BG, Lee DH, Ye BD et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007; 12: 31–5.
- 26 Kim JM, Kim JS, Jung HC, Kim N, Song IS. Antibiotic resistance of Helicobacter pylori isolated from Korean patients in 2003. Korean J. Gastroenterol. 2004; 44: 126–35.
- 27 Kim JM. Antibiotic resistance of Helicobacter pylori isolated from Korean patients. Korean J. Gastroenterol. 2006; 47: 337–49.
- 28 Hwang TJ, Kim N, Kim HB et al. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J. Clin. Gastroenterol. 2010; 44: 536–43.
- 29 Vaira D, Zullo A, Hassan C, Fiorini G, Vakil N. Sequential therapy for Helicobacter pylori eradication: the time is now! Therap. Adv. Gastroenterol. 2009; 2: 317–22.
- 30 Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin. Pharmacokinet. 1999; 36: 353–73.